Launch marks strategic milestone in Enalees' industrial and technological development, with first production plant set to become operational in France in 2026

Enalees, a French pioneer in rapid PCR tests for animal health, today announces the launch of Rhéa^®, its new range of rapid molecular diagnostic tests for cattle, sheep and goats. This innovation marks a strategic step in terms of R&D development for Enalees, following its international rollout of two ranges of tests – one for horses and the other for cats and dogs.

A reliable and rapid point-of-care diagnostic solution, designed especially for rural veterinarians

The Rhéa^® range addresses a growing need in the sector: enabling veterinarians to act quickly and accurately in the field, even in the most remote areas, by diagnosing, then treating, ruminants on site, without the need for a laboratory. The first panel test available, Rhéa Vector-Borne Diseases, simultaneously detects four major pathogens in under 40 minutes, directly in the field: Theileria spp., Babesia spp., Anaplasma spp. (including A. marginale and A. phagocytophilum), and Borrelia spp. These pathogens can also be detected in a monovalent format.

Together, these four pathogens can seriously affect the health and productivity of animals.

Accessible 24/7 without a cumbersome laboratory infrastructure (unlike traditional PCR tests), Rhéa guarantees veterinarians:

• Complete diagnostic autonomy
• Rapid clinical decision-making, for targeted treatment or immediate biosecurity measures
• Improved continuity in the agricultural sector's production and logistics chains

“Rhéa is a powerful symbol of our commitment; bringing innovation to field veterinarians using simple, reliable tools tailored to the demands of rural veterinary medicine,” said Laurent Thiery, president and co-founder of Enalees.

An innovation-driven approach supported by new financing and R&D efforts

The expansion of Enalees’ rapid test range to include the livestock sector opens up a market three times larger than that of the pet sector, offering targeted solutions for cattle, poultry, pigs, sheep and goats.

This innovation strategy has been made possible by the €15 million fundraising round completed in 2024, as well as support from the public France 2030 initiative– the Première Usine (First Factory) program - through which Enalees received a non-dilutive grant of €2.7 million in 2025 to build its first production plant in France.

The global veterinary diagnostics market is expected to reach $9.5 billion by 2026, exhibiting a CAGR of 10% during the forecast period. 

The Rhéa range of tests will be available from June 2025.